HLP
Hongli Group Inc. Ordinary Shares
Mentions (24Hr)
0.00% Today
Reddit Posts
HLP Hongli Group Inc shorted the floated
Feetr Data Dump: SNTG XYF HLP HUDI MEGL YGF TOP
HLP up 300%. Another Hong kong stock
Mentions
HLP Entered into Strategic Non-Binding MOU with Sidus Energy Storage, Inc. to Explore Potential Advanced Battery Manufacturing Collaboration https://www.stocktitan.net/news/HLP/hongli-group-inc-entered-into-strategic-non-binding-mou-with-sidus-s7ou0ebmtygn.html
>There are too many nested risks for me to take HL seriously. >Of course there's the standard protocol risk stuff. However there's also clearly economic risk given HLP got 'exploited' to take on bad debt. >Then there's the multiple bridges. A bridge from an already bridged chain.. yeah, that sounds like it will inevitably cause issues.
**Compass Pathways (CMPS):** A major player in the space, they are in Phase 3 trials for **psilocybin therapy** (COMP360) for treatment-resistant depression. Despite some previous regulatory friction, they are a primary candidate for the FDA's new "priority vouchers" mentioned in the order. **AtaiBeckley (ATAI):** Formed through the merger of Atai Life Sciences and Beckley Psytech, this company is researching several compounds, including **5-MeO-DMT** and **ibogaine** derivatives. Their stock saw significant movement following the announcement. **Beond, Inc.:** A U.S.-based company specializing in **ibogaine-assisted therapies**. They recently established a headquarters in Austin, Texas, and issued a statement confirming their intent to provide the "gold-standard" clinical model for the research framework established by the order. **Helus Pharma (formerly Cybin):** Recently rebranded in early 2026, Helus is advancing HLP003 (a proprietary psilocybin analog) through two pivotal Phase 3 studies. They already hold an FDA Breakthrough Therapy Designation, making them a direct beneficiary of the order's mandate to "dramatically accelerate" access. **Definium Therapeutics & Psyence Biomedical:** Both companies are actively conducting research on psychedelic-derived treatments for mental health and were highlighted by market analysts as key entities affected by the administration's policy shift.
If you have been margin called, then call: 1-800-HLP-RTRD And a fellow retard will be standing by for moral support Remember RTRD There's always the next trade
In the industry. Here’s a few things to consider: \ \ Bullish for HIMS \ 1) GLP-1s (Ozempic, Wegovy (both semaglutide), Mounjaro, Zepbound (both tirzepatide)) are taking the PBM and health plan industry by storm. Extreme demand. Not many covering it for weight loss. This drives consumers to companies like HIMS that dispense the drug for far less than the cost of official name brand drug./ 2) These drugs (GLP-1s) are a breakthrough in medicine and produce results that will continue to be in high demand for many, many years in the future. \ 2) HIMS just added a longtime Pharma executive from Novo Nordisk to its board. I see this as a positive sign the company will be able to navigate the compounding issues mentioned below. \ \ Bearish for HIMS \ 1) FDA rules only allow a compounding pharmacy (think HIMS supplier) to manufacturer copies of a brand drug when there is a drug shortage. Currently, the FDA has listed the HLP-1 drugs (Ozempic, etc.) as in a shortage. However, the million dollar question is, for how long. All weight loss medications HIMS dispenses are compounded. The HIMS supplier will be at extreme risk of FDA scrutiny once it becomes illegal to compound these weight loss products. In addition, compounding these drugs opens HIMS up to litigation from the drug manufacturers, Novo and Lily, both of which which are no stranger to using litigation to maximize profits.
I Didnt know that...lol. I seen HLP first time today someone mentioned it. I am so hopeful people take notice because this is the next CXAI easy. Look it up.
I hope it's not a rat trap. Yesterday HLP was also high at 300% and the opening went down like a brick. I think a lot of people got burned.